BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25987071)

  • 21. Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study.
    Florianova L; Xu B; Traboulsi S; Elmansi H; Tanguay S; Aprikian A; Kassouf W; Brimo F
    World J Surg Oncol; 2015 Nov; 13():317. PubMed ID: 26577765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.
    May M; Helke C; Nitzke T; Vogler H; Hoschke B
    Urol Int; 2004; 72(2):103-11. PubMed ID: 14963349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer.
    Abufaraj M; Shariat SF; Haitel A; Moschini M; Foerster B; Chłosta P; Gust K; Babjuk M; Briganti A; Karakiewicz PI; Albrecht W
    Urol Oncol; 2017 May; 35(5):264-271. PubMed ID: 28214283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer.
    Bergeron A; Picard V; LaRue H; Harel F; Hovington H; Lacombe L; Fradet Y
    Int J Cancer; 2009 Sep; 125(6):1365-71. PubMed ID: 19533752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low expression of TMEM67 is a critical predictor of poor prognosis in human urothelial carcinoma of the bladder.
    Du E; Zhang C; Qin Z; Yang K; Li C; Wang A; Zhang Z; Xu Y
    Urol Oncol; 2017 Apr; 35(4):152.e7-152.e12. PubMed ID: 28161324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary High-Grade Non-Muscle-Invasive Bladder Cancer: High NFκB Expression in Tumor Specimens Distinguishes Patients Who are at Risk for Disease Progression.
    Mitrakas L; Gravas S; Papandreou C; Koukoulis G; Karasavvidou F; Dimakopoulos G; Weingärtner K; Karatzas A; Zachos I; Tzortzis V
    Pathol Oncol Res; 2019 Jan; 25(1):225-231. PubMed ID: 29081034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence.
    Huang P; Chen J; Wang L; Na Y; Kaku H; Ueki H; Sasaki K; Yamaguchi K; Zhang K; Saika T; Nasu Y; Watanabe M; Kumon H
    Med Oncol; 2012 Jun; 29(2):829-34. PubMed ID: 21533858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
    Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
    Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of vascular invasion in patients with bladder cancer who underwent radical cystectomy.
    Harada K; Sakai I; Hara I; Eto H; Miyake H
    Int J Urol; 2005 Mar; 12(3):250-5. PubMed ID: 15828951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing CD 10 Expression Level and Its Prognostic Impact in Egyptian Patients with Urothelial Carcinoma.
    Hussien MT; Helmy E; Elsaba TM; Elkady A; Alrefai H; Hetta HF
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1573-1583. PubMed ID: 32592351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of special AT-rich sequence-binding protein 1 in endometrial cancer: a clinicopathologic study.
    Zhang Y; Wang L; Liu Y; Meng F; Wang S; Shang P; Gao Y; Chen X
    Int J Gynecol Cancer; 2015 Jan; 25(1):4-11. PubMed ID: 25347096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer.
    Huang B; Wang H; Lin H; Yao Z; Zheng J; Fan W; Qiu S; Chen L; Chen J
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):487-494. PubMed ID: 30539282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.
    Byrne RR; Shariat SF; Brown R; Kattan MW; Morton RA JR; Wheeler TM; Lerner SP
    J Urol; 2001 May; 165(5):1473-9. PubMed ID: 11342899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients.
    Keck B; Wach S; Taubert H; Zeiler S; Ott OJ; Kunath F; Hartmann A; Bertz S; Weiss C; Hönscheid P; Schellenburg S; Rödel C; Baretton GB; Sauer R; Fietkau R; Wullich B; Krause FS; Datta K; Muders MH
    Int J Cancer; 2015 Jan; 136(2):443-51. PubMed ID: 24862180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
    Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP
    J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression of Maspin in bladder carcinoma and the relationship between Maspin and lymph node metastasis].
    Tang Y; Zu X; Xiong Y; Zhang X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Dec; 40(12):1306-12. PubMed ID: 26739071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opa interacting protein 5 acts as an oncogene in bladder cancer.
    He X; Hou J; Ping J; Wen D; He J
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2221-2233. PubMed ID: 28752236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.